Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Halabi KC, Ross B, Acker KP, Cannon J-, Messina M, Mangino D, et al. Successful diagnostic stewardship for Clostridioides difficile testing in pediatrics. Infect Control Hosp Epidemiol. 2023;44(2):186-190.

Sarachakov A, Varlamova A, Svelolkin V, Polyakova M, Valencia I, Unkenholz C, et al. Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling. Blood. 2023.

Saoud C, Lam H, Gross JM, Ali SZ. Fine needle aspiration of bone lesions: A tertiary care centre experience. Cytopathology. 2023;34(6):562-572.

Assaad MA, Gundem G, Liechty B, Sboner A, Medina J, Papaemmanuil E, et al. The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. Cold Spring Harb Mol Case Stud. 2023;9(4).

Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, et al. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer. Cancer Res. 2023;83(4):506-520.

Li F, Wang Y, Hwang I, Jang J-, Xu L, Deng Z, et al. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance. bioRxiv. 2023.

Saldarriaga MM, Alhomoud M, Roboz G, Allan JN, Ruan J, Ouseph MM, et al. Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia. Am J Hematol. 2023;98(7):1119-1126.

Ruiz-Uribe NE, Bracko O, Swallow M, Omurzakov A, Dash S, Uchida H, et al. Vascular oxidative stress causes neutrophil arrest in brain capillaries, leading to decreased cerebral blood flow and contributing to memory impairment in a mouse model of Alzheimerâ€™s disease. bioRxiv. 2023.

Velu PD, Sipley J, Marino J, Ghanshani S, Lukose G, Cong L, et al. Evaluation of a Zoonotic Orthopoxvirus PCR Assay for the Detection of Mpox Virus Infection. J Mol Diagn. 2023;25(10):740-747.

Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231156147.